Grünenthal, a global pharmaceutical company based in Aachen, Germany, announced today that it has reached an agreement with Eli Lilly and Company to acquire the commercial rights to Cialis® (tadalafil) in Mexico, Brazil, and Colombia. This acquisition further strengthens Grünenthal’s presence in the Latin American market. As part of the deal, Grünenthal will also take over the manufacturing of Cialis® at its production site in Chile. The transaction is expected to be completed by the third quarter of 2025, subject to customary closing conditions.
Grünenthal CEO Gabriel Baertschi stated, “This strategic acquisition aligns with our goal of targeted purchases and will expand our existing portfolio in the region. We are excited to add Cialis® to our Latin American Men’s Health product line, and we look forward to working with Lilly to ensure a seamless transition for our customers.”
Cialis® is an oral treatment for erectile dysfunction and benign prostatic hyperplasia in adult men. The addition of Cialis® to its product portfolio will allow Grünenthal to provide a more comprehensive range of treatments for men’s health issues in Latin America.
This acquisition is in line with Grünenthal’s strategy of acquiring established medicines to grow its portfolio and increase profitability. Since 2017, the company has invested over €2 billion in the acquisition of established medicines, including Nebido®, Crestor®, Nexium®, Vimovo® (excluding the U.S. and Japan), Qutenza®, and Zomig® (excluding Japan). In 2023, Grünenthal established a joint venture with Kyowa Kirin International, called Grünenthal Meds, to manage a portfolio of 13 brands focused on pain management. In 2024, the company acquired Valinor Pharma and the product Movantik®.
Grünenthal’s CEO Baertschi added, “Our commitment to innovation and improving patient lives is at the core of everything we do. With this acquisition, we are further expanding our product portfolio and strengthening our position as a leader in pain management and related diseases.”
For more information about Grünenthal, please visit www.grunenthal.com. Follow the company on LinkedIn at Grunenthal Group and on Instagram at grunenthal.
For media inquiries, please contact:
Maren Thurow
Head of Global Communication
Grünenthal GmbH
52099 Aachen
E-Mail: Maren.Thurow@grunenthal.com
Phone: +44 7917 196855
In Mexico, Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.
Distributed by https://pressat.co.uk/